Printer Friendly

Cancer surgery questioned.

Researchers have found that for older men with prostate cancer in its early stages, doing nothing but watching and waiting may be better than surgery, the increasingly popular approach among doctors.

In a study in the Journal of the American Medical Association, researchers found that men over 65 who received aggressive treatment lived less than a year longer on average than those whose cancer was simply monitored.

A second study found that the rate of radical prostatectomy--removal of the prostate gland--increased nearly sixfold from 1984 to 1990 among Medicare patients. All of the patients in that study were over 65.

"We have, in essence, an epidemic of treatment and no scientific proof that it's valid," said Dr. John Wasson, who worked on both studies.

Cancer of the prostate, a chestnut-shaped male gland beneath the bladder, is the most common cancer in American men. It will cause an estimated 35,000 deaths this year. Many prostate cancers grow slowly and may not invade other tissues for years. For such men, the immediate risk of complications from treatment may not be worth trying to buy extra years of life, the study said. Such men are likely to die of other causes before their malignancies spread and cause problems.

The first study found that men ages 65 to 70 with localized prostate cancers lived, on average, 14.1 years after diagnosis if their cancers were just watched, compared with 14.2 years for men who underwent radical prostatectomy and 14.3 years for men who received radiation.

Treatment costs run from $15,000 to $25,000, Wasson said.
COPYRIGHT 1993 Association of Labor Assistants & Childbirth Educators
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:for prostate cancer
Publication:Special Delivery
Date:Jun 22, 1993
Previous Article:Testing for sickle cell urged.
Next Article:Fear, surrender and transformation in birth.

Related Articles
Prostate screen: blood test rates best.
Benefits of prostate therapy questioned.
Revising the risk of prostate surgery.
Impotence high after prostate removal.
Selected Ongoing Clinical Trials [*].
Section on Urology. (Abstracts of Scientific Posters).
Predicting prostate cancer's moves: new tests could refine therapy decisions.
Watch and wait, or not: studies weigh risks of delaying prostate surgery.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters